Latest News & Features
Americas
Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description. 18 January 2022
Americas
The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma. 18 January 2022
Americas
Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid. 17 January 2022
Medtech
Arthrex says that it did not get the “remedy” ordered by the US Supreme Court in its landmark case against Smith & Nephew. 13 January 2022
Big Pharma
Oral diagnostics company PeriRx has lost a patent licensing suit against the University of California and research company RNAmeTRIX, claiming that they had breached sublicensing agreements. 13 January 2022
Big Pharma
Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment. 13 January 2022
Big Pharma
Roche unit Chugai failed to persuade the US Patent Trial and Appeal Board that it should not institute inter partes reviews of a patent covering Actemra, a treatment for arthritis under the NHK/Fintiv rule. 11 January 2022
Biotechnology
Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy. 11 January 2022
Americas
A former Monsanto employee has pled guilty to conspiring to steal trade secrets from the biotech company in order to share the information with the Chinese government. 10 January 2022
Americas
Sarepta Therapeutics won’t be able to rely on a “safe harbour” provision to protect its gene therapy invention from a patent infringement suit from biotech Regenxbio and the University of Pennsylvania, a Delaware court has ruled. 6 January 2022